Tiziana to seek FDA's nod to begin Alzheimer's drug trial; shares up

Tiziana Life Sciences

12/10/2022 14:18

** Shares of Tiziana Life Sciences Ltd  TLSA.O  rise 7.5% to
$0.80 premarket
    ** Co says it plans to submit an application for early-stage
trial of its experimental intranasal drug, foralumab, in
Alzheimer's disease patients  urn:newsml:reuters.com:*:nGNE6QXsnd
    ** TLSA plans to submit the application by Q3 of 2023, start
early-stage study by end 2023 
    ** Foralumab is also being evaluated in patients with
Crohn's disease
    ** As of last close, stock down ~23% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))